Skip to main content


Correction to: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer

Article metrics

  • 360 Accesses

The original article was published in Journal of Hematology & Oncology 2019 12:56

Correction to: J Hematol Oncol (2019) 12:56

The original article [1] contains an error in Fig. 2 whereby Fig. 2d has mistakenly been omitted. Figure 2 can be viewed in its entirety – including Fig. 2d – in this Correction article.

Fig. 2

Characterization of tumor derived exosomes and EVs. The size and morphology of exosomes were evaluated by dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) (a) and transmission electron microscopy (TEM) (b), respectively. The yield of DNA was 3.4-fold higher in LXY30-enriched exosomes than in S-LXY30-enriched exosomes (3.4 ± 0.7 vs 1.0 ± 0.2 ng/μL, p = 0.014) (c). Driven mutations (EGFR L858R and T790 M in H1975) were detected by PCR and Sanger sequencing in the DNA isolated from LXY30 exosomes (d)


  1. 1.

    Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, et al. High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer. J Hematol Oncol. 2019;12:56

Download references

Author information

Correspondence to Kit S. Lam or Tianhong Li.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark